-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3024 Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma

Program: Oral and Poster Abstracts
Session: 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Adult, Research, Translational Research, Non-Hodgkin lymphoma, Epidemiology, Lymphomas, B Cell lymphoma, Clinical Research, Genomics, Diseases, Indolent lymphoma, Lymphoid Malignancies, Biological Processes, Study Population, Human
Sunday, December 8, 2024, 6:00 PM-8:00 PM

Anath Lionel, MD, PhD1, Sherif Seif, MD2*, Xiaowen Sun3*, Lei Feng, MS3*, Lorenzo Gensini, MD2*, Bria Gabriel2*, Lauren S. Lewis2*, Hima Bansal, PhD2*, Melody R. Becnel, MD2, Mahmoud R. Gaballa, MD2, Hans C. Lee, MD2, Oren Pasvolsky, MD2, Krina K. Patel, MD, MSc2, J Christine Ye, MD, MSc2, Keyur P. Patel, MBBS, PhD4, Donna M. Weber, MD2, Robert Z. Orlowski, MD, PhD2 and Sheeba K. Thomas, MD2

1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Oakville, ON, Canada
2Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Background:

Lymphoplasmacytic lymphoma (LPL) is an indolent B-cell neoplasm, of which the most common subtype is Waldenström macroglobulinemia (WM). Somatic mutations affecting MYD88 and CXCR4 are found in over 90% and 40% of patients with WM respectively, and these 2 genes are part of routine clinical testing. While the negative prognostic effect of TP53 mutations is well-established in diseases such as multiple myeloma and CLL, their impact in WM is less well-characterized. Moreover, the clinical presentation of patients with TP53 mutations has not previously been described. We conducted a retrospective single-institution analysis to evaluate the impact of TP53 mutations in patients with LPL/WM and IgM monoclonal gammopathy of undetermined significance (MGUS).

Methods:

All patients (n=255) with a diagnosis of either WM, non-IgM LPL or IgM MGUS, who had undergone next generation sequencing (NGS) gene panel testing on a bone marrow sample performed at our institution, were included in this analysis. For patients who had NGS testing on more than one date, the earliest NGS panel test results were used. Between 6/2016-9/2020, the 29-gene EndCancer panel was used (n=116), and between 10/2020-4/2024, the 162-gene EndLymphoma panel was used (n=139). While some genes, including TP53, MYD88 and CXCR4, were captured by both NGS panels, others including IGLL5 and ARID1A, were only tested as part of the EndLymphoma panel. Both panels had >250x coverage of the 10 coding exons of TP53 (total 394 codons) except for a short stretch of 7 codons from exon 3 missing in both panels, and 5 codons from exon 4 missing only in the EndCancer panel. Overall survival (OS) was calculated from time of first NGS panel for all patients; survival metrics were compared using log rank tests.

Results:

The median age of the study population (n=255) at LPL/WM or IgM MGUS diagnosis was 71 years (range 32-97); 145 were male (57%), and 228 (89%) self-identified race as White or Caucasian. At the time of NGS panel testing, 155 (61%) had symptomatic WM, 73 (29%) had smoldering WM, 14 (5%) had symptomatic non-IgM LPL, 10 (4%) had smoldering non-IgM LPL and 3 (1%) had IgM MGUS. Median time from initial diagnosis to NGS testing was 18 months (range: 0-283.5 months), and median length of follow-up after NGS testing was 31.5 months (95% CI: 26.0 – 39.3 months).

Genes with the highest percentage of mutations were MYD88 (187/255; 73%), CXCR4 (79/255; 31%), IGLL5 (36/139; 26%), ARID1A (16/139; 11.5%) and TP53 (28/255; 11%). TP53 mutations were most common in patients with symptomatic WM (26/155), followed by those with symptomatic non-IgM LPL (1/14), and smoldering WM (1/73); no patients with smoldering non-IgM LPL (0/10) or IgM MGUS (0/3) exhibited these mutations.

TP53 mutations were associated with shorter median overall survival (OS) (50.4 vs. not reached, p <0.0001), and a significantly higher risk of death (hazard ratio (HR) 5.5; 95% CI: 2.6-11.6). On univariate analyses of MYD88, CXCR4, IGLL5 and ARID1A, none were predictive of OS. However, by multivariate analysis of TP53, MYD88 and CXCR4 mutations, TP53 mutations were an independent predictor of overall survival (p <0.0001; HR 5.3; 95% CI: 2.4-11.8). Sub-group analysis of patients with MYD88 mutations (n=187) further revealed that those with TP53 mutations (n=23) had a significantly worse prognosis (p<0.0001; HR 7.2; 95% CI:2.9-17.8) regardless of CXCR4 mutation status.

On review of disease features, no statistically significant differences were noted in the incidences of neuropathy (43 vs 40%), hyperviscosity (21 vs 17%), Bing Neel syndrome (7 vs 2%), bone lesions (7 vs 6%), acquired von Willebrand disease (0 vs 3%) and cold agglutinin hemolytic anemia (4 vs 3%) between those with and without TP53 mutations.

Conclusions:

In our analysis of patients with WM, non-IgM LPL, and IgM MGUS, the most frequently mutated genes were MYD88, CXCR4, IGLL5, ARID1A and TP53. Despite having similar clinical features, patients with TP53 mutations had a significantly reduced overall survival and increased risk of death compared to those without these mutations. The prognostic significance of TP53 suggests that TP53 mutation testing should be a part of routine clinical testing for LPL/WM patients. Novel therapeutic strategies are needed to improve the outcomes of LPL/WM patients with TP53 mutations.

Disclosures: Gaballa: Guidepoint: Consultancy; GLG: Consultancy; Boxer Capital, LLC: Consultancy; Bristol Myers Squibb: Consultancy. Lee: Abbvie: Consultancy; Takeda: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Regeneron: Consultancy, Research Funding; Amgen: Research Funding; GlaxoSmithKline: Consultancy, Research Funding; Pfizer: Consultancy; Allogene: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding; Sanofi: Consultancy. Patel: Sanofi: Consultancy; AstraZeneca: Consultancy; Kite, A Gilead company: Consultancy, Other: scientific advisory board; Takeda: Consultancy; Abbvie: Consultancy; BMS: Consultancy, Other: chair of scientific advisory board ; Poseida: Consultancy; Genentech: Consultancy; Johnson & Johnson (Janssen): Consultancy; Caribou Sciences: Consultancy; Merck: Consultancy; Pfizer: Consultancy; Oricel: Consultancy, Other: Chair of scientific board. Orlowski: Bristol-Myers Squibb Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Asylia Therapeutics Inc.: Current equity holder in private company, Patents & Royalties; Sanofi, Takeda Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Research Funding; BioTheryX: Membership on an entity's Board of Directors or advisory committees, Research Funding; DEM BioPharma, Inc., Karyopharm Therapeutics, Lytica Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, Myeloma 360, Nanjing IASO Biotherapeutics, Neoleukin Corporation, Oncopeptides AB, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sporos Bio: Membership on an entity's Board of Directors or advisory committees; AbbVie Inc, Adaptive Biotechnologies Corporation, Asylia Therapeutics Inc, BioTheryX Inc, Bristol Myers Squibb, Karyopharm Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, Nanjing IASO Biotherapeutics, Neoleukin Therapeutics, Oncopeptides, Pf: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb, CARsgen Therapeutics, Exelixis Inc, Heidelberg Pharma, Janssen Biotech Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Laboratory Research Funding: Asylia Therapeutics Inc, BioTheryX Inc, Heidelberg Pharma: Research Funding. Thomas: Janssen: Research Funding; Abbvie: Consultancy, Research Funding; University of Texas MD Anderson Cancer Center: Current Employment; X4 Pharma: Research Funding; Genentech: Research Funding; Cellectar Biosciences: Consultancy, Honoraria, Research Funding; Mustang Bio: Consultancy, Honoraria; Sanofi: Research Funding; Bristol Myers Squibb: Research Funding; Acerta Pharma: Research Funding; Ascentage Pharma: Research Funding.

*signifies non-member of ASH